Your Messages Inbox
Your Article Summary
See Latest ArticlesArray BioPharma Announces Top-Line Results from Rheumatoid Arthritis Phase 2 Trial
Array BioPharma, 09/04/09
Array BioPharma Inc. announced its preliminary analysis of results from a study examining ARRY–162, a small molecule MEK inhibitor, in a 12–week Phase 2 clinical trial with 201 patients. The patients had active rheumatoid arthritis that was not completely responsive to methotrexate. This study included a placebo group and three different dose groups of ARRY–162, all on a stable background of methotrexate.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
The Unintended Consequences of Clinical Trials Regulations
PLoS Medicine, 12/04/09
Characterization of Baseline Methicillin-Resistant Staphylococcus aureus Isolates Recovered from Phase IV Clinical Trial for Linezolid
Journal of Clinical Microbiology, 12/03/09
Bayer Starts Phase III Trial with Florbetaben
BayNews International, 12/01/09
Article Search
Sponsor